Can-Fite BioPharma Updates SEC Filings with Press Release Reference
Ticker: CANF · Form: 6-K · Filed: Feb 28, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Feb 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: SEC-filing, compliance, biopharma, regulatory-update
TL;DR
**Can-Fite BioPharma just updated its SEC registration statements by incorporating a recent press release, making that info officially part of its public record.**
AI Summary
Can-Fite BioPharma Ltd. filed a Form 6-K on February 28, 2024, indicating it is a foreign private issuer. The filing incorporates by reference the first paragraph of an attached press release into several of its Registration Statements, including Form S-8 (File Nos. 333-227753 and 333-271384) and Form F-3 (File Nos. 333-195124, 333-236064, 333-249063, 333-262055, and 333-276000). This action ensures that the information from the press release becomes part of these registration statements as of the filing date.
Why It Matters
This filing ensures that public investors have access to the most current information from Can-Fite BioPharma's press release, which is now formally part of its active registration statements, impacting transparency and compliance.
Risk Assessment
Risk Level: low — This is a routine compliance filing that updates existing registration statements with new information, posing minimal direct risk.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Registrant and foreign private issuer
- February 28, 2024 (date) — Date of 6-K filing and report period
- Form 6-K (document) — Type of SEC filing
- Form S-8 (document) — Registration statement type
- Form F-3 (document) — Registration statement type
- 333-227753 (document) — File number for Form S-8
- 333-271384 (document) — File number for Form S-8
- 333-195124 (document) — File number for Form F-3
- 333-236064 (document) — File number for Form F-3
- 333-249063 (document) — File number for Form F-3
FAQ
What is the purpose of this 6-K filing by Can-Fite BioPharma Ltd.?
The purpose of this 6-K filing is to report as a foreign private issuer and to incorporate by reference the first paragraph of an attached press release into several of its existing Registration Statements on Form S-8 and Form F-3.
Which specific registration statements are affected by this filing?
The filing affects Registration Statements on Form S-8 (File Nos. 333-227753 and 333-271384) and Form F-3 (File Nos. 333-195124, 333-236064, 333-249063, 333-262055, and 333-276000).
When was this 6-K report filed?
This 6-K report was filed on February 28, 2024.
What information from the press release is being incorporated by reference?
Only the first paragraph of the press release attached to this Form 6-K is being incorporated by reference.
What is Can-Fite BioPharma Ltd.'s Commission File Number?
Can-Fite BioPharma Ltd.'s Commission File Number is 001-36203.
Filing Stats: 274 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2024-02-28 07:06:42
Filing Documents
- ea0200857-6k_canfite.htm (6-K) — 10KB
- ea0200857ex99-1_canfite.htm (EX-99.1) — 13KB
- 0001213900-24-017744.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: February 28, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 2